Restricting routine CD4 monitoring to after 52 weeks following ART initiation and removing toxicity testing was associated with an incremental cost-effectiveness ratio of $ 6084 per quality-adjusted life-year ( QALY ) across all age groups , but was much lower for older children ( 12 + years at initiation ; incremental cost-effectiveness ratio = $ 769/QALY ) .